NAS:XENT (USA)
Business Description
Intersect ENT Inc
NAICS : 339112
SIC : 3841
1555 Adams Drive, Menlo Park, CA, USA, 94025
Description
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.32 | |||||
| Equity-to-Asset | -0.74 | |||||
| Debt-to-Equity | -1.68 | |||||
| Debt-to-EBITDA | -0.99 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.82 | |||||
| Beneish M-Score | -3.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.6 | |||||
| 3-Year EBITDA Growth Rate | -86.6 | |||||
| 3-Year EPS without NRI Growth Rate | -84.8 | |||||
| 3-Year FCF Growth Rate | -52 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.92 | |||||
| 9-Day RSI | 69.25 | |||||
| 14-Day RSI | 64.96 | |||||
| 6-1 Month Momentum % | 3.17 | |||||
| 12-1 Month Momentum % | 56.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.88 | |||||
| Quick Ratio | 1.5 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 211.33 | |||||
| Days Sales Outstanding | 53.02 | |||||
| Days Payable | 107.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.88 | |||||
| Operating Margin % | -75.23 | |||||
| Net Margin % | -161.94 | |||||
| ROA % | -92.17 | |||||
| ROIC % | -64.08 | |||||
| ROC (Joel Greenblatt) % | -768.84 | |||||
| ROCE % | -121.27 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.08 | |||||
| EV-to-EBIT | -6.53 | |||||
| EV-to-EBITDA | -6.7 | |||||
| EV-to-Revenue | 10.21 | |||||
| EV-to-Forward-Revenue | 8.12 | |||||
| EV-to-FCF | -14.9 | |||||
| Earnings Yield (Greenblatt) % | -15.31 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:XENT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 103.995 | ||
| EPS (TTM) ($) | -5.04 | ||
| Beta | 0 | ||
| Volatility % | 45.54 | ||
| 14-Day RSI | 64.96 | ||
| 14-Day ATR ($) | 0.184988 | ||
| 20-Day SMA ($) | 27.92 | ||
| 12-1 Month Momentum % | 56.28 | ||
| 52-Week Range ($) | 15.92 - 28.25 | ||
| Shares Outstanding (Mil) | 33.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intersect ENT Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||